Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Decreases By 13.9%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 430,841 shares, a decrease of 13.9% from the March 15th total of 500,465 shares. Based on an average daily trading volume, of 851,376 shares, the short-interest ratio is presently 0.5 days. Currently, 17.0% of the shares of the company are sold short.

Analysts Set New Price Targets

ASBP has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aspire Biopharma Stock Down 10.1%

Shares of NASDAQ:ASBP opened at $0.27 on Friday. The company has a market cap of $725,493.00, a P/E ratio of -0.01 and a beta of 0.99. Aspire Biopharma has a 52 week low of $0.25 and a 52 week high of $35.01. The company has a 50-day moving average price of $1.13 and a 200 day moving average price of $4.72.

Aspire Biopharma (NASDAQ:ASBP) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.06) EPS for the quarter. The company had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Aspire Biopharma

Hedge funds have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. acquired a new stake in Aspire Biopharma in the third quarter valued at about $28,000. XTX Topco Ltd increased its holdings in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after buying an additional 237,620 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after buying an additional 131,533 shares in the last quarter. Institutional investors and hedge funds own 19.17% of the company’s stock.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.